# Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

> **NCT01806571** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 34 (actual)

## Conditions studied

- Untreated Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** Cytarabine
- **DRUG:** Daunorubicin Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Nilotinib
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01806571
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-12
- **Primary completion:** 2017-07-31
- **Final completion:** 2019-11-30
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2023-05-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01806571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01806571, "Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01806571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*